Abstract
A 55 years old male patient, who is planned for bronchoscopy developed central anti-cholinergic syndrome due to therapeutic dose of atropine. Withdrawal of atropine has improved the symptoms. Thereafter, instillation of atropine as eye drops leads to reappearance of symptoms. The reaction was definite according to Naranjo’s algorithm. It was severe and definitely preventable according to Modified Hartwig and Siegel’s scale and Modified Schumock and Thornton scale respectively. Central anti-cholinergic syndrome may be due to variation in the genetic susceptibility (Idiosyncrasy) to atropine. Idiosyncratic reaction on administration of atropine as a pre-anesthetic medication or eye drops should be kept in mind while prescribing.
Keywords: Adverse drug reaction, Anti-cholinergic drugs, Atropine, Central anti-cholinergic syndrome, Pre-anesthetic medication, Eye drops
Current Drug Safety
Title:Central Anti-Cholinergic Syndrome Induced by Single Therapeutic Dose of Atropine
Volume: 7 Issue: 1
Author(s): Ashwin Panchasara, Divyesh Mandavia, Ashish P. Anovadiya and C. B. Tripathi
Affiliation:
Keywords: Adverse drug reaction, Anti-cholinergic drugs, Atropine, Central anti-cholinergic syndrome, Pre-anesthetic medication, Eye drops
Abstract: A 55 years old male patient, who is planned for bronchoscopy developed central anti-cholinergic syndrome due to therapeutic dose of atropine. Withdrawal of atropine has improved the symptoms. Thereafter, instillation of atropine as eye drops leads to reappearance of symptoms. The reaction was definite according to Naranjo’s algorithm. It was severe and definitely preventable according to Modified Hartwig and Siegel’s scale and Modified Schumock and Thornton scale respectively. Central anti-cholinergic syndrome may be due to variation in the genetic susceptibility (Idiosyncrasy) to atropine. Idiosyncratic reaction on administration of atropine as a pre-anesthetic medication or eye drops should be kept in mind while prescribing.
Export Options
About this article
Cite this article as:
Panchasara Ashwin, Mandavia Divyesh, P. Anovadiya Ashish and B. Tripathi C., Central Anti-Cholinergic Syndrome Induced by Single Therapeutic Dose of Atropine, Current Drug Safety 2012; 7 (1) . https://dx.doi.org/10.2174/157488612800492799
DOI https://dx.doi.org/10.2174/157488612800492799 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Serotonergic and Cholinergic Strategies as Potential Targets for the Treatment of Schizophrenia
Current Pharmaceutical Design Nutraceuticals against Neurodegeneration: A Mechanistic Insight
Current Neuropharmacology ABC Transporters in Extrahepatic Tissues: Pharmacological Regulation in Heart and Intestine
Current Medicinal Chemistry Opening New Scenarios for Human MAO Inhibitors
Central Nervous System Agents in Medicinal Chemistry Neuroprotective Strategies in Glaucoma
Current Pharmaceutical Design Inflammation and Neurogenesis in Temporal Lobe Epilepsy
Current Drug Targets - CNS & Neurological Disorders A Genetic Dissection of Antipsychotic Induced Movement Disorders
Current Medicinal Chemistry Neuronal and Extraneuronal Nicotinic Acetylcholine Receptors
Current Neuropharmacology N-Valproyl-L-Phenylalanine as New Potential Antiepileptic Drug: Synthesis, Characterization and In Vitro Studies on Stability, Toxicity and Anticonvulsant Efficacy
Medicinal Chemistry Molecular Mechanism of a Specific NLRP3 Inhibitor to Alleviate Seizure Severity Induced by Pentylenetetrazole
Current Molecular Pharmacology Neurological Disorders of Purine and Pyrimidine Metabolism
Current Topics in Medicinal Chemistry Machine Learning, Molecular Modeling, and QSAR Studies on Natural Products Against Alzheimer’s Disease
Current Medicinal Chemistry Management of Antiepileptic Treatment After Epilepsy Surgery - Practices and Problems
Current Pharmaceutical Design Adenosine Receptors: What We Know and What We are Learning
Current Topics in Medicinal Chemistry Editorial (Thematic Issue: Mitochondrial Biogenesis: Pharmacological Approaches)
Current Pharmaceutical Design ATP-Sensitive Potassium Channels
Current Pharmaceutical Design Editorial:Metabolic, Pathological, and Therapeutic Perspectives Intracellular 5’-Nucleotidases.
Current Medicinal Chemistry Recent Advancements in Nanodiamond Mediated Brain Targeted Drug Delivery and Bioimaging of Brain Ailments: A Holistic Review
Pharmaceutical Nanotechnology AMPA Receptor Antagonists as Potential Anticonvulsant Drugs
Current Topics in Medicinal Chemistry Why Anticancer Nanomedicine Needs Sugars?
Current Medicinal Chemistry